anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Infrared thermography (IRT) is an essential non-invasive method for analyzing surface temperature variations in animals, offering valuable insights into livestock stress responses. Despite their resilience, goats can face significant challenges under extreme conditions like heat-stress and water deprivation. This experiment aimed to delineate the dynamic variations in whole-body and scrotal surface temperatures in goats subjected to the combined impact of both conditions using IRT. Eight healthy Aardi bucks were exposed to three 72-h treatments: euhydration, dehydration, and rehydration. Continuous meteorological monitoring provided ambient-temperature, relative-humidity, and temperature-humidity index (THI) values. Surface temperatures were measured twice daily at 08:00 and 15:00, and thermal gradients between ambient and body or scrotal surface temperatures were computed. Based on the obtained mean THI values, the bucks experienced heat-stress throughout the experiment. Additionally, results revealed noticeable variations in both surface temperatures across treatments and time points, indicated by measures of central tendency, variability, shape descriptors, and frequency distribution of temperature. Morning measurements indicated lower temperatures and gradients under euhydration, while water deprivation led to higher temperatures and compromised thermal regulation. Conversely, afternoon data showed higher variability in temperature responses, highlighting the compounded effect of diurnal heat-stress and water deprivation. Although water-restoration mitigated some effects of deprivation, it did not fully restore thermal homeostasis to euhydrated levels. Thermal gradients further emphasized the goats' dynamic thermoregulatory mechanisms, which were compromised under water deprivation, particularly in the scrotal region, but were partially restored upon restoration. These findings demonstrate the effectiveness of IRT in assessing thermal responses in goats and underscore the importance of adequate hydration for maintaining thermal balance under heat-stress. The herein performed profiling provides valuable insights with implications for overall health, reproductive efficiency, productivity, and welfare in heat-stressed and water-deprived goats, which might offer a framework for future research on livestock adaptation to such challenging environmental conditions.
Prepn. comprises preparing a fine particle compsn. obtd. by grinding mixt. of nifedipine, casein, and one or at least two substances of magnesium silicate, magnesium carbonate, dried aluminium hydroxide gel, magnesium oxide, metasilicate magnesium aluminate, synthetic hydrotarsite, and alumina magnesium hydroxide; then grinding fine article together with an enteric coating agent and an plastic agent; and dry granulating obtd. compsn. - Pren. comprises prepg. a fine particle compsn. obtd. by grinding mixt., of nifedipine, casein, and one or at least two substances of magnesium silicate, magnesium carbonate, dried aluminium hydroxide gel, magnesium oxide, metasilicate magnesium aluminate, synthetic hydrotarsite, and alumina agnesium aluminate, synthetic hydrotarsite, and alumina hydroxide, hydroxide; then grinding fine particle together wtih an enteric coating agent, an plasticising agent and higher fatty acid ester; and dry granulating obtd. compsn. - Pref. enteric coating agent is one substance or a mixt. of at least two substances of phthalic acid acetate cellulose, hydroxy propyl methyl cellulose phthalate, methyl methacrylic acid copolymer, polyvinyl acetate phthalate, cellulose acetate succinate, and styrene maleic acid copolymer. Plasticising agent is selected from polyethylene glycol, polyoxyethylene sorbitan monooleate, propylene glycol, and acethylated monoglyceride. Higher fatty acid ester is selected from cane sugar fatty acid ester, sorbitan fatty acid ester, and glycerin fatty acid ester.
<P>PROBLEM TO BE SOLVED: To provide a pack cosmetic which does not need a support, is used for removing cornoid lamellas, and has the same cornoid lamella-removing action as that of a pack agent.  <P>SOLUTION: This peel-off pack not having a support contains natural fibers. The natural fibers include vegetable fibers such as cotton, linen, jute, Musa basjoo, Broussonetica kazinoki, Edgeworthia papyrifera, or kenaf, or animal fibers such as wool, alpaca hair, rabbit hair, raccoon dog hair, or fox hair. Of these, the vegetable fibers are preferable in terms of dispersibility in an aqueous carrier. The vegetable fibers waved in some extent are preferable on the improvement in the strength characteristic of the coating film. Concretely, linen and/or jute are particularly preferable.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
Childhood anxiety disorders are quite common and associated with significant psychosocial impairment and distress. Offering equivalent efficacy to pharmacotherapy without the common side effect profile, cognitive behavioral therapy (CBT) is a first line treatment for anxiety disorders in youth. However, dissemination of CBT to community settings is very limited. Effective treatment via traditional CBT often necessitates that the patient travel to a center that specializes in this treatment, and cost can prove an impediment to those of lower socioeconomic status, in particular. As well, differing theoretical approaches and training result in a minority of children with anxiety receiving evidence-based CBT. Accordingly, there is a great need for more widely accessible practices. As such, we are proposing a two phase trial that evaluates the feasibility of implementing a patient-centered intervention in community mental health centers, followed by an efficacy trial. In Phase I, an open trial of computerized CBT (CCBT) will be completed that focuses on feasibility issues of providing this intervention in community mental health centers. Thereafter, we will complete a randomized controlled trial comparing CCBT to treatment as usual (TAU) in Phase II. The open trial will recruit 18 youth ages 7 to 13 years, with the purpose of testing both practicality and management of an already developed CCBT protocol (Kendall \& Khanna, 2008). The outcome trial will recruit 110 youth, with the purpose of measuring the efficacy of the CCBT protocol in front-line settings. Significantly greater symptom reductions in the CCBT group as compared to the TAU group would provide critical evidence for the inclusion of CCBT as a treatment option for anxious youth without immediate access to such in-person care. While this study will be coordinated by the University of South Florida Rothman Center for Neuropsychiatry team who is located at All Children's Hospital (USF/ACH), recruitment will take place at three community mental health centers throughout Florida that serve families of lower socioeconomic status. Primary outcomes will be assessed by an independent evaluator, and will include change in anxiety symptom severity; response rates; and remission rates. CCBT will follow the Kendall and Khanna (2008) manual with appropriate integrity checks. The implications of this study are significant, as computerized CBT may enable widespread dissemination of efficacious therapy for anxiety disorders among youth.
Dilute VYVGART prior to administration. Administer via intravenous infusion only [see Dosage and Administration (2.3)].

The recommended dosage of VYVGART is 10 mg/kg administered as an intravenous infusion over one hour once weekly for 4 weeks. In patients weighing 120 kg or more, the recommended dose of VYVGART is 1200 mg (3 vials) per infusion.

Administer subsequent treatment cycles based on clinical evaluation. The safety of initiating subsequent cycles sooner than 50 days from the start of the previous treatment cycle has not been established.

If a scheduled infusion is missed, VYVGART may be administered up to 3 days after the scheduled time point. Thereafter, resume the original dosing schedule until the treatment cycle is completed.
An emulsion that consisted of 50 mg of cisplatin and 10 mL of lipiodol at a volume ratio of 1:1 was injected into the blood supply artery of the tumor under fluoroscopic guidance. The injection could be slowed or discontinued if retrograde flow occurred. Embolization was subsequently performed with granules of gelatin sponge particles.
Disclosed is a nutritional supplement composition for the prevention, reduction or treatment of radiation injury due to exposure to ionizing radiation. The composition includes: one or more compounds that regulates cell differentiation and/or cell proliferation, such as vitamin D3, 1(S),3(R)-dihydroxy-20(R)-(1-ethoxy-5-ethyl-5-hydroxy-2heptyn-1-yl)-9,10-seco-pregna-5(Z),7(E),10(19)-triene, compounds that may be converted or metabolized into vitamin D3 in the human body, metabolites thereof, and pharmaceutically acceptable salts thereof, and one or more antioxidants such as alpha-lipoic acid and chlorophyllin or pharmaceutically acceptable salts thereof; optionally formulated in a pharmaceutically acceptable carrier for an oral composition. The composition may further include optional ingredients such as flavonoids, flavonoid derivatives, selenium, selenium compounds, anti-inflammatories, organic germanium, Korean ginseng, American ginseng, Siberian ginseng and B-complex vitamins. A method for the administration of an oral composition for the purpose of preventing, reducing or treating radiation injury involves orally administering an effective amount of a composition including one or more compounds that regulates cell differentiation and/or cell proliferation, and one or more antioxidants to a person before, during or after radiation exposure. A method for the topical administration of the composition for the purpose of preventing, reducing or treating radiation injury involves topically administering an effective amount of the composition to an area of skin, which has been or will be exposed to ionizing radiation. The compositions and methods can be employed to prevent, reduce or treat radiation injury caused by a wide variety of types of radiation exposure.
1452532 Anti-perspirant compositions L J ORREN 12 Feb 1974 [9 March 1973] 06312/74 Heading A5B Anti-perspirant compositions contain as the active ingredient an astringent aluminium salt (e.g. aluminium chlorhydrate or aluminium chloride), a dermatologically acceptable vehicle and a cosmetically acceptable reducing agent in an amount sufficient to inhibit staining of fabric in contact with the composition and perspiration, the reducing agent being water-dispersible, essentially non-odorous, and being selected from inorganic sulphur-containing salts, organic bisulphites in which the bisulphite group has replaced the hydrogen atom of an amino group, adducts of sulphur dioxide formed by reaction between aldehydes or ketones and sodium bisulphite or zinc bisulphite, inorganic phosphorus - containing salts, an organic substituted phosphine compound and dermatologically acceptable stannous or titanous salts. The reducing agent may be a sulphite, bisulphite, hydrosulphite, meta-bisulphite or thiosulphate e.g. ammonium sulphite, an alkali metal sulphite, an alkaline earth metal sulphite, zinc sulphite, ammonium bisulphite, an alkali metal bisulphite or an alkaline earth metal bisulphite, sodium dithionite, zinc dithionite, alkali metal (e.g. Na or k) metabisulphite, alkali metal (e.g. Na) or alkaline earth metal (e.g. Ca) thiosulphates, monoethanolamine bisulphite, urea bisulphite, guanidine bisulphite, ethylamine bisulphites, ethylenediamine bisulphite, sodium formaldehyde bisulphite, sodium formaldehyde sulphoxylate, zinc formaldehyde sulphoxylate, acetone sodium bisulphite, ammonium hypophosphite, alkali metal (e.g. Na) hypophosphite or alkaline earth metal (e.g. Ca) hypophosphite or a corresponding phosphite, tetrakis (hydroxymethyl) phosphonium chloride; stannous chloride, stannous bromide, stannous tartrate, stannous acetate, stannous sulphate, titanous chloride or titanous bromide. The compositions may be in the form of. emulsions, aerosols, suspensions, creams or lotions and may also contain fillers, propellants, perfumes, surfactants and/or fabric corrosion inhibitors such as glycine or alanine.
Clinical manifestations of phlebosclerotic colitis (PC) exhibit significant variability, necessitating diverse treatment strategies depending on disease severity. However, there is limited research exploring the relationship between imaging findings and disease severity. Hence, this retrospective study aimed to analyze the correlation between computed tomography (CT) findings, colonoscopic features, and disease severity. This study compared the abdominal CT characteristics, colonoscopy findings, and treatment modalities of 45 PC patients. CT images were assessed for the severity of mesenteric venous calcification, maximum colonic wall thickness, number of involved colonic segments, and presence of pericolic inflammation. Colonoscopic images were assessed for dark purple discoloration mucosa, erosive and ulcerative lesions, mucosal edema, luminal narrowing, and the number of involved colonic segments. In addition, patients were categorized into three groups: the observation (n = 15), medical treatment (n = 19), and operation (n = 11) groups. In CT images, a significant difference in pericolic inflammation (p = 0.039) was observed among groups. Further, significant differences in dark purple discoloration mucosa (p = 0.033), erosive or ulcerative lesions (p < 0.001), mucosal edema (p < 0.001), luminal narrowing (p = 0.012), and the number of involved colonic segments (p = 0.001) were observed in colonoscopy. Moreover, we found positive correlations between CT and colonoscopy features. In conclusion, CT manifestations and colonoscopy findings exhibited correlation with disease severity in PC. When limited to one diagnostic tool, observations from that tool can infer potential manifestations of the alternative tool.
We were the first to test 4-phenylbutyrate (Buphenyl) as a systemic corrector of these defects in F508del under an investigator-initiated Investigational New Drug (IND)application held by P. Zeitlin. In a series of Phase 1 and 2 trials we established the maximum tolerated dose as 20 gm daily divided t.i.d. and the maximum induction of cyclic AMP (cAMP)-mediated nasal epithelial chloride transport with 30 gm daily as a median of -10 millivolt (mV) on days 4 and 7 of treatment.1;2 Under those conditions there was no significant decrease in sweat chloride values or in amiloride-inhibited nasal potential difference (NPD). We interpreted these results as a proof of concept of corrector therapy, but corrector therapy alone was likely an insufficient therapy for this mutation in CF, and therefore closed the IND for 4-phenylbutyrate.

In the ensuing years, Vertex Pharmaceuticals, Inc. has had success with the development of ivacaftor3;3;4 (VX-770) as a potentiator of G551D CFTR and has studied the drug alone and in combination with their corrector lumacaftor5 (VX-809) and VX-661. We at Johns Hopkins University (JHU), University of Alabama at Birmingham (UAB) and Childrens' Hospital of Philadelphia/University of Pennsylvania (CHOP/Penn) have participated in many of the clinical trials and are pleased and encouraged by the success of VX-770. It is not yet certain that future combinations of corrector(s) and potentiator(s) will be safe and effective, and it is prudent to explore alternative correctors and potentiators. Furthermore, recent structural investigations in a number of laboratories support the idea that more than one corrector may be necessary to fully restore F508del to the trafficking pathway 6. Precedent for combination of 4PBA with other CFTR modulators has been established in vitro 7;8 4-Phenylbutyrate tablets are formulated for oral delivery, and we showed that the pharmacokinetics were similar in CF to that in patients with urea cycle disorders. However the large number of tablets that had to be ingested at each meal were somewhat daunting at the 30 gm daily dose. A new pro-drug of 4-phenylbutyrate, glycerol phenylbutyrate or Ravicti®(owned by Hyperion Pharmaceuticals, Inc.) was approved in February 2013 by the US FDA. This new formulation is a significant advance for patients with urea cycle disorders because it is an oral, odorless, tasteless liquid, that contains 3 molecules of 4-phenylbutyrate for every molecule of the triglyceride. Simple arithmetic would suggest that one mole equivalent of the pro-drug provides three moles of active drug. However, pancreatic lipase enzymes are required to break the covalent bonds and release the active drug in the intestines. Because most CF patients homozygous for F508del are pancreatic-insufficient and already on enzyme therapy, we propose to test the effectiveness of the combination of CF pancreatic enzyme replacement therapy (PERT) on absorption of Ravicti® and subsequent restoration of nasal epithelial CFTR-mediated chloride transport during the nasal potential difference (NPD) test.
FIELD: medicine, immunology, prophylaxis. SUBSTANCE: method deals with algae therapy by adding into a diet at average daily dose of 0.5-0.6 g sea algae for 14 days, at repeated course in two weeks. Moreover, to decrease treatment course inhaling process is conducted by inhalation of 15-20% solution of sea algae decoction, and to prevent and lengthen remission at paroxysmal period - daily for 20 days per 20-30 minutes. Treatment course is conducted in algae chamber by inhaling air vapors produced by air-dried algae at the room temperature at equilibrium concentration at the rate of the content of 5 kg algae at chamber volume being approximately 30 square meters. EFFECT: higher efficiency of therapy due to decreased terms of treatment, prophylaxis and remission of paroxysms at bronchial asthma and allergic bronchitis, decreased quantity of pharmacological preparations during therapy course. 3 cl, 2 tbl
The study is designed as a prospective, multi-center trial conducted at 2 centers in Germany enrolling up to 12 subjects. Each patient will be followed for 2 years. The last patient's follow-up will end in February 2016. It is planned that the study will end in June 2016. Study endpoints are defined in accordance with the "Standardized endpoint definitions for transcatheter aortic valve implantation clinical trials: a consensus report from the Valve Academic Research Consortium (VARC-2)". These endpoint definitions combine the expertise of surgeons, interventionalists, medical cardiologists, clinical trial and other specialists and allow for comparison of different trials concerning effectiveness and safety in TAVI.
BACKGROUND: In extremely preterm infants, persistence of cardioventilatory events is associated with long-term morbidity. Therefore, the objective was to characterize physiologic growth curves of apnea, periodic breathing, intermittent hypoxemia, and bradycardia in extremely preterm infants during the first few months of life.
METHODS: The Prematurity-Related Ventilatory Control study included 717 preterm infants <29 weeks gestation. Waveforms were downloaded from bedside monitors with a novel sharing analytics strategy utilized to run software locally, with summary data sent to the Data Coordinating Center for compilation.
RESULTS: Apnea, periodic breathing, and intermittent hypoxemia events rose from day 3 of life then fell to near-resolution by 8-12 weeks of age. Apnea/intermittent hypoxemia were inversely correlated with gestational age, peaking at 3-4 weeks of age. Periodic breathing was positively correlated with gestational age peaking at 31-33 weeks postmenstrual age. Females had more periodic breathing but less intermittent hypoxemia/bradycardia. White infants had more apnea/periodic breathing/intermittent hypoxemia. Infants never receiving mechanical ventilation followed similar postnatal trajectories but with less apnea and intermittent hypoxemia, and more periodic breathing.
CONCLUSIONS: Cardioventilatory events peak during the first month of life but the actual postnatal trajectory is dependent on the type of event, race, sex and use of mechanical ventilation.
IMPACT: Physiologic curves of cardiorespiratory events in extremely preterm-born infants offer (1) objective measures to assess individual patient courses and (2) guides for research into control of ventilation, biomarkers and outcomes. Presented are updated maturational trajectories of apnea, periodic breathing, intermittent hypoxemia, and bradycardia in 717 infants born <29 weeks gestation from the multi-site NHLBI-funded Pre-Vent study. Cardioventilatory events peak during the first month of life but the actual postnatal trajectory is dependent on the type of event, race, sex and use of mechanical ventilation. Different time courses for apnea and periodic breathing suggest different maturational mechanisms.
Provided in the present invention are a pharmaceutical composition and a health functional food containing a compound separated from a Dendropanax morbifera lev. extract for preventing or treating cancer. Moreover, provided is a method for preparing a triterpenoid compound, which comprises the following steps: a first step of preparing a Dendropanax morbifera lev. extract from Dendropanax morbifera lev.by applying water including purified water, lower alcohol of C1 to C4, hexane, or a mixed solvent of the same; a second step of preparing Dendropanax morbifera lev. fraction by performing system fraction of the Dendropanax morbifera lev. Extract prepared in the first step; and a third step of preparing beta-amyrin, alpha-amyrin, dendropanoxide, beta-sitosterol or stigmasterol.
<P>PROBLEM TO BE SOLVED: To obtain a resistance overcoming agent that overcomes resistance to an anticancer agent in a cancer having resistance.  <P>SOLUTION: The overcoming agent for anticancer agent resistance comprises an AR inhibiting compound as an active ingredient. The AR inhibiting compound is used for production of an anticancer agent resistance overcoming agent. The pharmaceutical composition comprises an AR inhibiting compound and an anticancer activity having compound. The method of screening an overcoming agent for anticancer agent resistance comprises assessing a compound having AR inhibiting activity by means of an evaluation system for anticancer agent resistance overcoming to thereby select a highly effective compound. The method of treating resistant cancer comprises administration of an AR inhibitor combined with an anticancer agent to a patient. Fidarestat is preferably used as the AR inhibiting compound.  <P>COPYRIGHT: (C)2007,JPO&INPIT